Introduction {#S1}
============

In large parts of the world, *Plasmodium vivax* is the dominant species causing human malaria [@R1],[@R2]. An effective blood-stage vaccine would reduce morbidity, lower blood-stage asexual and sexual parasite densities and aid progress towards elimination. The symptoms of malaria occur as parasites invade, replicate within and burst out of red blood cells (RBC) of infected individuals. *Plasmodium vivax* parasites invade immature RBC, selecting reticulocytes expressing transferrin receptor CD71 [@R3],[@R4]. *Plasmodium vivax* Duffy-binding protein, *Pv*DBP, interacts with the Duffy antigen receptor for chemokines, DARC/Fy, on the surface of reticulocytes, and is essential for invasion by most strains [@R5],[@R6]. Indeed, genetic knockout of the orthologous DBPα gene from the closely-related simian malaria *Plasmodium knowlesi* also prevents invasion of Duffy-positive erythrocytes *in vitro* [@R7] and antibodies that target *Pk*DBP can block invasion of erythrocytes by *Plasmodium knowlesi* [@R8]. Moreover, a human polymorphism which results in Duffy-negative erythrocytes [@R9] is widespread across Africa and is associated with protection from *Plasmodium vivax* infection [@R10], leading to low levels of this form of malaria across much of the continent [@R11]. *Pv*DBP is therefore the most promising candidate for inclusion in a vaccine to prevent *Plasmodium vivax* [@R12].

*Pv*DBP has been divided into six distinct regions, with the DARC binding site mapped to a \~350 amino acid residue Duffy-binding-like (DBL) domain known as Region II, *Pv*DBPII[@R6]. This domain is split into three regions, known as subdomains 1-3 [@R5]. *Pv*DBPII binds to the sixty-residue extracellular N-terminal ectodomain of DARC, in an interaction which requires DARC to be post-translationally modified by sulphation of two tyrosine residues, Tyr30 and Tyr41 [@R13],[@R14]. Nevertheless, the interaction between *Pv*DBPII and DARC is only partially understood. Structural studies of *Pv*DBPII show it to form dimers in both solution and in a crystal [@R13]. In addition, structures of *Pv*DBPII crystallised in the presence of the ectodomain of DARC, reveal an ordered 11-residue helical peptide (DARC~19-30~), which lies close to the *Pv*DBPII dimer interface in subdomain 2 [@R15]. However, the DARC protein used in these studies was not tyrosine-sulphated and sulphated Tyr41, which cannot be seen in this study, was previously shown to be essential for high affinity *Pv*DBPII binding [@R14]. Indeed, mapping residues identified by mutagenesis onto the structure of *Pv*DBPII reveals an additional patch on subdomain 2 proposed to contribute to DARC binding [@R16],[@R17] and it is likely that the DARC binding site spans much of the surface of subdomain 2, including both this patch and the region that interacts with the helical DARC~19-30~ peptide.

Development of *Pv*DBPII-based vaccine candidates has progressed through pre-clinical studies to two recent Phase I human clinical trials[@R18],[@R19]. Immunisation of mice, rabbits and non-human primates using *Pv*DBPII-based vaccines induces inhibitory antibodies that block binding of recombinant *Pv*DBPII to DARC [@R20],[@R21]. Challenges in sustaining *Plasmodium vivax* in long-term culture [@R22] have prevented these antibodies from being robustly tested in standardised functional growth inhibition assays, of the type traditionally performed for vaccines targeting *Plasmodium falciparum* [@R12]. Nevertheless, in humans, high-titres of naturally-acquired antibodies that target *Pv*DBPII and prevent DARC binding *in vitro* are associated with reduced risk of *Plasmodium vivax* infection [@R23], lower parasite densities following invasion and decreased risk of clinical malaria [@R24],[@R25]. Encouragingly, in a recent Phase Ia clinical trial, immunisation of human volunteers using recombinant viral vectors expressing *Pv*DBPII induced strain-transcending antibodies which prevented recombinant *Pv*DBPII from binding to DARC [@R19], confirming that such antibodies could be raised by human vaccination.

Several studies have investigated the molecular basis for antibody-mediated inhibition of DARC binding by *Pv*DBPII [@R13],[@R15],[@R26],[@R27]. Screening a linear peptide array with non-inhibitory and inhibitory human serum identified peptides which recognise antibodies found specifically in inhibitory serum [@R27]. These peptides are located within subdomain 2, in regions involved in *Pv*DBPII dimerisation and DARC~19-30~ peptide binding [@R15], suggesting that antibodies which directly block dimerisation and DARC binding are desirable. In addition, a study of monoclonal antibodies (mAbs) derived from *Pv*DBPII-immunised mice used structural studies and mass-spectrometry based mapping approaches to identify three epitopes for antibodies shown to block DARC binding *in vitro* [@R26]. Surprisingly, these epitopes are located on subdomain 3 of *Pv*DBPII, distant from the DARC binding site.

To understand the epitopes for human inhibitory antibodies, and to guide future structure-guided immunogen development, we have now cloned a panel of antibodies from *Pv*DBPII immunised human volunteers. We determined their ability to inhibit binding of recombinant *Pv*DBPII to DARC *in vitro*, as well as their capacity to neutralise parasite invasion in two distinct parasite-based functional assays. This provides important insight into these different *in vitro* readouts of antibody function and led to the structural characterisation of an epitope for an antibody that shows broadly neutralising activity against parasite invasion.

Results {#S2}
=======

Cloning of a panel of vaccine-induced human monoclonal antibodies that bind to *Pv*DBPII {#S3}
----------------------------------------------------------------------------------------

A panel of anti-*Pv*DBPII mAbs was isolated from antibody-secreting cells of immunised volunteers enrolled in a human Phase Ia clinical trial of a *Pv*DBPII-based vaccine delivered using recombinant chimpanzee adenovirus and poxvirus viral vectors [@R19]. RT-PCR and PCR were used to isolate variable region (VR)-coding genes and these were cloned into a human IgG1 scaffold. Cognate heavy-chain and light-chain plasmids were co-expressed in HEK293 cells and vaccine antigen-specificity confirmed by ELISA reactivity of culture supernatants to recombinant *Pv*DBPII. Ten genetically distinct mAbs were isolated ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), which recognised parasite-derived *Pv*DBP from culture supernatant ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). These were aligned with the most similar germline VR genes in IgBLAST [@R28], showing them to contain little non-germline sequence. Their monovalent binding affinities for *Pv*DBPII, as determined by surface plasmon resonance (SPR) ([Figure 1A-D](#F1){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}), reveal low nanomolar to high picomolar affinities. Assessment of their binding to biotinylated *Pv*DBPII by Biolayer Interferometry (BLI) ([Figure 1E,F](#F1){ref-type="fig"}) defined two distinct epitope bins containing mAbs which bind overlapping epitopes, and three mAbs with distinct non-overlapping epitopes ([Figure 1G](#F1){ref-type="fig"}). An ELISA-based binding inhibition assay [@R29] was used to assess their inhibition of binding of five sequence-divergent *Pv*DBPII proteins [@R19] to DARC ([Figure 2](#F2){ref-type="fig"}, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Most mAbs showed differential binding inhibition, with only two (DB2 and DB9) inhibiting the DARC binding of all five *Pv*DBPII variant alleles ([Figure 2](#F2){ref-type="fig"}).

Assessing the neutralisation of parasite invasion by the antibody panel {#S4}
-----------------------------------------------------------------------

To characterise the ability of the human mAbs to block merozoite entry into RBC, assays of growth inhibition activity (GIA) were performed. A *Plasmodium knowlesi* line was used that has been adapted to long-term *in vitro* culture in human RBC [@R30] and in which the native *Pk*DBPα gene had been replaced by the *Pv*DBP gene [@R31]. *Plasmodium knowlesi* is dependent on DARC for RBC invasion, but unlike *Plasmodium vivax*, has three DBP genes; *Pk*DBPα, *Pk*DBPβ and *Pk*DBPγ [@R32]. Both *Pk*DBPβ and *Pk*DBPγ are thought to be required for invasion of rhesus RBC whereas *Pk*DBPα is essential for invasion of human RBC [@R7],[@R33],[@R34]. The ten mAbs were assayed for growth inhibition against five *Plasmodium knowlesi* lines. First, the original human-RBC adapted PkA1-H.1 strain [@R30]. Second, two transgenic PkA1-H.1 lines, *Pv*DBP^OR^ in which the *Pk*DBPα gene had been replaced with the *Pv*DBP gene (this transgenic insert was the full-length *Pv*DBP Salvador I (SalI) strain vaccine-homologous sequence), and *Pv*DBP^OR^/Δβγ, in which the same gene swap had taken place and additionally the native *Pk*DBPβ and *Pk*DBPγ genes had been deleted. *Pv*DBP^OR^/Δβγ was considered the best model for *Plasmodium vivax* as the only DBP gene present is that for *Pv*DBP. Finally, were two transgenic control lines, *Pk*DBPα^OR^ and *Pk*DBPα^OR^/Δβγ in which native *Pk*DBP genes had been deleted and replaced with re-codonised versions of themselves.

One anti-*Pv*DBPII mAbs, DB7, at high concentration, inhibited growth of the three *Plasmodium knowlesi* control lines ([Figure 3A](#F3){ref-type="fig"}), suggesting an epitope cross-reactive with PkDBPα. In contrast, when assayed against the transgenic *Pv*DBP-expressing *Plasmodium knowlesi* lines, three mAbs showed high levels of inhibition of parasite growth, with four showing intermediate levels and the remaining three showing modest activity. A control human mAb against *Ebolavirus* showed no detectable GIA ([Figure 3A](#F3){ref-type="fig"}). The three most neutralising anti-*Pv*DBPII mAbs (DB1, DB9 and DB10) had EC~50~ values comparable to mouse-derived mAbs which potently prevent erythrocyte invasion by *Plasmodium falciparum* [@R35],[@R36]. A strong correlation (*P* = 0.002, ρ=-0.951) was observed between the association-rate (*k*~on~) and GIA ([Figure 3B](#F3){ref-type="fig"}), suggesting that the opportunity for *Pv*DBP blockade in the context of merozoite invasion is time-limited [@R36],[@R37]. In contrast, no correlation was observed between GIA and either dissociation rate or affinity ([Figure 3B](#F3){ref-type="fig"}).

To assess the degree of strain transcendence of mAb inhibition across naturally occurring isolates, we next tested the mAbs directly for their capacity to prevent reticulocyte invasion by *Plasmodium vivax* parasites derived from thirteen clinical isolates originating from Thai patients, using *ex-vivo* short-term culture invasion inhibition assays ([Figure 4A,B](#F4){ref-type="fig"}). Limited availability of these clinical samples prevented us from assessing the inhibitory potential of every antibody against every isolate. We were able to sequence the *Pv*DBPII gene region from eight of these isolates, revealing multiple polymorphisms ([Figure 4C](#F4){ref-type="fig"}). Some isolates had *Pv*DBPII sequences identical to the SalI reference strain used in the vaccine (\#4 and \#7) while others were polymorphic, with as many as ten amino acid substitutions in region II of the DBP gene (\#6 and \#8).

These assays revealed marked strain-dependent differences in the potency of the anti-*Pv*DBPII mAbs. For example, DB1 and DB10, the two most inhibitory mAbs in the transgenic *Plasmodium knowlesi* GIA assay (containing the SalI *Pv*DBP transgene), inhibited invasion of Thai isolates with matching SalI *Pv*DBPII sequences (isolates \#4 and \#7) but not those with heterologous *Pv*DBPII sequences (isolates \#5 and \#8) ([Figure 4B,D](#F4){ref-type="fig"}). Notably, the hierarchy of mAb potency for the two *Plasmodium vivax* parasite isolates which possessed the homologous SalI *Pv*DBPII sequence mirrored that observed in the transgenic *Plasmodium knowlesi* model ([Figure 4B](#F4){ref-type="fig"}), suggesting that this model is highly predictive of *Plasmodium vivax* neutralisation. DB3, 5, 6 and 7 showed intermediate median levels of inhibition (\~40-60 %), whilst DB2, 4 and 8 showed low median levels (\~10-20 %). Only one of the ten mAbs (DB9) potently inhibited invasion (\~65-90 %) of 10/11 isolates. The inhibition of invasion by isolate 12 was lower but a lack of sequence information, due to the challenges of working with small quantities of samples from field isolates, makes it challenging to speculate on the reasons for this. DB9 also showed potent growth inhibition in the transgenic *Plasmodium knowlesi* assays of GIA ([Figure 3A](#F3){ref-type="fig"}) and inhibited binding of all five variant alleles of *Pv*DBPII to DARC ([Figure 2](#F2){ref-type="fig"}), highlighting it as an antibody with broadly neutralising activity against a wide range of *Plasmodium vivax* variants.

Antagonism of DB9-mediated inhibitory activity {#S5}
----------------------------------------------

We next sought to assess whether the efficacy of DB9 would be enhanced or diminished by the other nine mAbs. A BLI binding-competition assay ([Figure 1E-G](#F1){ref-type="fig"}), showed that half of the mAbs, including DB9, compete with each other for binding sites on recombinant *Pv*DBPII. To test for evidence of synergy, additivity or antagonism [@R38], we ran GIA assays using the *Pv*DBP^OR^ line of transgenic *Plasmodium knowlesi* in which DB9 was present at 25 μg/mL, together with a dilution series of a second mAb ([Figure 5](#F5){ref-type="fig"}). While no synergy was detected, there was antagonism between DB9 and five other mAbs, with addition of a second mAb leading to growth inhibition lower than that predicted from adding the inhibition due to the individual mAbs at equivalent concentrations. Surprisingly, these were the five mAbs (DB1, DB4, DB5, DB7 and DB10) which did not compete with DB9 for binding to *Pv*DBPII in the BLI competition assay ([Figure 1E-G](#F1){ref-type="fig"}). The other four mAbs (DB2, DB3, DB6 and DB8) with epitopes overlapping that of DB9, showed an additive growth inhibitory effect with DB9 in this assay. Therefore, antibodies that bind in and around the DB9 epitope function in an independent and additive manner, whilst antibodies that bind to distinct epitope regions elsewhere on the *Pv*DBPII molecule are mutually antagonistic. Given DB9 was able to show strain-transcending high-level neutralising activity, this raised the imperative to understand the epitope of DB9 and thus enable future design of immunogens which specifically induce DB9-like antibodies.

The molecular basis for the action of DB9 {#S6}
-----------------------------------------

To obtain structural insight, we crystallised a complex of PvDBPII bound to the Fab fragment of DB9. Crystals diffracted to 3.0 Å resolution, allowing structure determination by molecular replacement ([Figure 6](#F6){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Comparison of the structure of *Pv*DBPII in complex with DB9 with that of un-liganded *Pv*DBPII (PDB: 4NUV) revealed no change in *Pv*DBPII conformation (with an RMSD of 0.523Å).

The epitope of DB9 is contained within subdomain 3 of *Pv*DBPII ([Figure 6A](#F6){ref-type="fig"}). This region consists of two long α-helices (H1 and H2), which form a platform on which three small helices (H3-H5) and their intervening loops are arranged ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). All three CDR loops of the heavy chain and CDR1 and CDR2 of the light chain directly contact *Pv*DBPII ([Supplementary Figure 3 and Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The epitope includes a single residue from H1 (K412) of *Pv*DBPII and residues from each of helices H3, H4 and H5, and the intervening loops. Contacts are predominantly mediated by hydrogen bonds between DB9 and hydrophilic residues from *Pv*DBPII.

We next compared the position of the epitope with locations of known polymorphic residues on *Pv*DBPII, as alignment of globally disparate sequences of *Pv*DBPII revealed 120 polymorphic sites with nucleotide diversity varying between 0.006 and 0.0109 [@R39]. We retrieved 383 amino acid sequences of *Pv*DBPII and calculated their sequence entropies. This revealed that the surface of *Pv*DBPII contacted by DB9 is one of the most conserved regions of the domain, with low sequence variation explaining its broadly reactive nature ([Figure 6B](#F6){ref-type="fig"} and [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

In the membrane context, *Pv*DBPII is thought to form a dimer which interacts with the extracellular domains of DARC. A crystal structure is available for a dimer of *Pv*DBPII bound to a small helix, consisting of residues 19-30 of the extracellular ectodomain of DARC [@R15]. We next superimposed our *Pv*DBPII:DB9 structure onto this structure, suggesting a model for how DB9 might inhibit invasion by *Plasmodium vivax* ([Figure 6C](#F6){ref-type="fig"}). While DB9 binds at a distance from the known region of the DARC binding site, it protrudes from subdomain 3 in the same direction as the C-terminus of the DARC~19-30~ peptide. This end of the DARC peptide will face the transmembrane region of DARC, located in the reticulocyte membrane. Although the arrangement of DARC~31-60~ is currently unknown, this model suggests that DB9 can prevent the *Pv*DBPII dimer from approaching the reticulocyte membrane in an orientation which is compatible with DARC binding, thereby preventing initiation of the invasion process.

With the epitope for DB9 contained solely within subdomain 3, we next assessed binding of the other mAbs bind to this region. Subdomain 3 was produced by refolding material expressed in *E. coli*. An ELISA-based binding assay showed that 6 of the 10 mAbs bound subdomain 3 ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). With the exception of DB4, these were the mAbs that competed for binding on *Pv*DBPII ([Figure 1E-G](#F1){ref-type="fig"}). Indeed, with the exception of DB4, the mAbs that bind to subdomain 3 are not those that antagonise the effect of DB9. Therefore, despite the fact that antibodies that target subdomain 3 differ in their inhibitory potential, these data identify subdomain 3 of *Pv*DBPII as a promising potential target for broadly inhibitory antibodies, and identify the epitope of one such antibody.

Discussion {#S7}
==========

The Duffy-binding protein is the most promising candidate for inclusion in a vaccine to prevent infection by *Plasmodium vivax* due to its essential interaction with human DARC during reticulocyte invasion. Antibodies which bind to *Pv*DBP are found in individuals from malaria endemic regions, and their presence associates with protection from clinical vivax malaria [@R23]--[@R25]. However, no human monoclonal antibody has been reported which targets *Pv*DBP and displays broadly inhibitory potential. We have therefore vaccinated human volunteers with *Pv*DBPII to induce a humoral response and isolated a monoclonal antibody which can inhibit all tested isolates of *Plasmodium vivax* from invading blood cells. This opens the possibility for testing the efficacy of this monoclonal as a prophylactic to prevent vivax malaria, while knowledge of its epitope will guide future vaccine development.

The mAbs generated here have been analysed through a series of complementary approaches and the differing outcomes of these assays illustrate the need for caution in attributing broadly inhibitory potential ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). The most accessible assay involves analysis of purified protein binding in an ELISA-based format, with antibodies assessed for prevention of recombinant *Pv*DBPII from binding to N-terminal DARC ectodomain, with the assumption that direct prevention of DARC binding is the goal for a protective antibody. This assay allows assessment of a range of *Pv*DBPII variants to analyse breadth of inhibitory potential and identified two antibodies that broadly inhibited DARC binding (DB9 and DB2), and three with vaccine-homologous (SalI sequence) binding-inhibition activity (DB5, DB6 and DB7).

With the blood-stage of *Plasmodium vivax* currently impossible to sustain in long-term *in vitro* culture conditions, we also used a culture-compatible transgenic parasite-based assay involving the closely related simian malaria, *Plasmodium knowlesi*. Here Duffy-binding protein, *Pk*DBPα was replaced by *Pv*DBP, generating parasite lines in which human RBC invasion inhibition can be studied in a laboratory setting using long-term culture. This showed a clear hierarchy of mAb potency against transgenic parasites *in vitro*, whether or not the *Pk*DBPβ and *Pk*DBPγ genes were removed. Most informatively, the outcomes of this study only partially overlapped with those of the protein-based study, with some antibodies (i.e. DB1 and DB10) among those with the greatest potency to block parasite invasion but proving ineffective at blocking the *Pv*DBPII-DARC interaction in a protein-protein assay. The failure of the binding-inhibition ELISA, which only uses fragments of DARC and *Pv*DBP, to predict parasite neutralisation in both subsequent functional assays, calls into question its utility as a method of screening antibodies in this context, suggesting that future studies should instead use parasite-based growth inhibition studies.

Finally, we used the most authentic *in vitro* assay available, by assessing the invasion of reticulocytes by *ex-vivo Plasmodium vivax* taken directly from patient isolates. When studying parasite isolates which expressed the SalI *Pv*DBPII variant incorporated into the transgenic *Plasmodium knowlesi* strain, these studies give a very similar outcome to the transgenic *Plasmodium knowlesi* assays ([Figures 3A](#F3){ref-type="fig"} and [4B](#F4){ref-type="fig"}). However, when studying isolates with heterologous *Pv*DBPII sequences, the outcomes were different. Here, just one antibody, DB9, inhibited reticulocyte invasion by all tested strains. Comparison of data from these three assays suggests that a protein-protein analysis will miss valuable inhibitory antibodies and highlights the applicability of a transgenic *Plasmodium knowlesi*-based assay as an accessible *in vitro* proxy for the *ex-vivo* analysis of *Plasmodium vivax*. In the future, panels of transgenic parasites expressing different *Pv*DBPII variants will allow assessment of broadly-inhibitory potential of therapeutic interventions.

Various properties have been suggested as desirable for inhibitory antibodies that target *Pv*DBP, including capacity to directly block DARC binding or to inhibit dimerisation [@R6],[@R13]. In contrast, DB9 binds distantly from either the DARC-binding or dimerisation interfaces, on a non-polymorphic site on the distal surface of subdomain 3. Remarkably, it also prevents recombinant *Pv*DBPII from binding to DARC immobilised onto an ELISA plate. A composite model, in which DB9 is docked onto that of a dimer of *Pv*DBPII bound to the 19-30 peptide from DARC shows that DB9 emerges from the same side of *Pv*DBPII as the C-terminus of the DARC peptide. DB9 may therefore sterically prevent dimeric *Pv*DBPII from approaching a DARC coated surface and thereby prevent receptor engagement and invasion. A previous study identified antibodies from immunised mice which also bind to subdomain 3 [@R26]. The inhibitory potential of these antibodies was tested using the protein-based binding assay, which we found to be only partially indicative of efficacy in parasite-based neutralisation assays. Nevertheless, one of these antibodies, 2C6, has an epitope close to that of DB9 ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}) and could be operating through the same mechanism.

These findings have significant consequences for vaccine development, identifying subdomain 3 of *Pv*DBPII as an important site of broadly-inhibitory epitopes for human antibodies. Not all antibodies that bind to subdomain 3 are inhibitory. However, our discovery of antibodies which bind to *Pv*DBPII and antagonise the function of DB9 also raises the imperative to avoid inducing these deleterious antibodies. While further studies are needed to understand the molecular basis for this antagonism, perhaps involving analysis of their effect on the interaction between full length PvDBP and DARC in the membrane context, it is encouraging to note that 80% of the antibodies that antagonise the function of DB9 do not recognise subdomain 3. This suggests future vaccination strategies in which the surface of subdomain 3 containing the DB9 epitope is specifically presented to the immune system in the form of a vaccine immunogen to produce a strong and protective immune response as part of the malaria vaccines of the future.

Methods {#S8}
=======

Generation of monoclonal antibodies {#S9}
-----------------------------------

### Plasmablast isolation and sorting {#S10}

Volunteers from a Phase Ia clinical trial were bled seven days after the second immunisation using MVA (modified vaccinia virus Ankara) encoding *Pv*DBPII [@R19]. Blood was collected from volunteers in heparinised tubes and centrifuged in Leucosep tubes (Greiner Bio-One) to separate the peripheral blood mononuclear cells (PBMC). The PBMC were enriched for B cells using a human pan-B cell enrichment kit (Easysep) and re-suspended in DMEM before staining with a CD19^+^, CD10^--^, CD21^--^, CD27^+^, CD20^--^, CD38^+^, IgG^+^ fluorophore-conjugated antibody panel. Plasmablasts were single-cell sorted using a MoFlo cell sorter (DakoCytomation) into 96-well PCR plates containing 10 μL 10 mM Tris HCl buffer containing 40 U/mL of RNase inhibitor (Promega). The study received ethical approval from the Oxfordshire Research Ethics Committee A in the UK (REC reference 13/SC/0001) and was registered with ClinicalTrials.gov NCT01816113. The volunteers signed consent forms and consent was verified before each vaccination.

### Antibody variable gene amplification {#S11}

In wells of a 96-well plate, each containing a single antibody-secreting cell (ASC), a two-step RT-PCR was carried out with a first reverse transcription (RT) step using a Sensiscript RT kit (Qiagen) and degenerate primers 1-17 (modified from [@R40], see [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Next, a PCR was performed on 1 μL of the RT reaction product using the same set of primers used before (1-17) which cover the diversity of all Vγ, Vκ and Vλ sequences using Phusion HF master mix (New England Biolabs). Following this, a nested PCR was performed with primers 18-51, also using Phusion HF master mix, ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}) on 1 μL of the previous product diluted 1:100 to amplify inserts which contain plasmid-homologous extensions designed for circular polymerase extension cloning [@R41].

### Cloning {#S12}

The AbVec-hIgG1/AbVec-hIgKappa/AbVec-hIgLambda expression plasmids were a kind gift from Patrick C. Wilson (University of Chicago) [@R42]. These plasmids were 5' digested using BshTI and at the 3' using SalI (AbVec-hIgG1), XhoI (AbVec-hIgLambda) and Pfl23II (AbVec-hIgKappa) to yield linear products. CPEC assembly was performed by mixing 100 ng of a 1:1 molar ratio of insert:plasmid in 20 μL containing 1x Phusion HF polymerase master mix and assembled using an 8-cycle CPEC protocol (8 cycles: 98 °C 10 s, slow ramp anneal from 70 °C to 55 °C at 0.1 °C/s, 72 °C 35 s). Full nicked plasmids were then transformed into Zymo 5α Mix & go competent *E. coli* (Zymo Research) according to manufacturer's instructions, streaked on LB agar petri dishes containing 100 μg/mL carbenicillin and grown at 37°C overnight in a static incubator. Colonies were screened by PCR for correctly sized inserts.

### Screening {#S13}

Exponential growth-phase adherent HEK293 cells were re-suspended in DMEM (Sigma-Aldrich) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 1 mM sodium pyruvate, 0.1 mg/mL streptomycin and 10 % ultra-low IgG foetal bovine serum (FBS) (Thermo Fischer Scientific) and seeded at 4 x 10^4^ cells/well in 100 μL 24 h prior to transfection in Costar 96-well cell culture plates (Corning). On the day of transfection, for each well, 50 μL of 60 μg/mL linear 25 kDa PEI (Alfa Aesar) was mixed with 200 ng of cognate heavy- and light-chain coding plasmid in a volume of 50 μL and shaken at 20°C for 30 min. The DNA-PEI complexes were added to the HEK293 cells. The following day, an additional 50 μL of supplemented DMEM (as described above) was added to each well. Supernatants were screened for *Pv*DBPII (produced in S2 cells as described below) binding by indirect ELISA. Over 100 mAb supernatants were screened in this assay and of these, ten bound *Pv*DBPII.

Recombinant protein constructs, expression and purification {#S14}
-----------------------------------------------------------

The production of the recombinant *Pv*DBPII used in the IgG screening assay described above, the DARC-binding inhibition assays ([Figure 2](#F2){ref-type="fig"}) and the SPR assays ([Figure 1A-D](#F1){ref-type="fig"}), from *Drosophila* S2 cells has been previously described [@R19]. In brief; the sequence used was identical to the vaccine sequence; D194--T521 of *Pv*DBPII (SalI), with T257A, S353A and T422A substitutions to remove sites of possible N-linked glycosylation, followed by a shortened Pk/V5 epitope tag (IPNPLLGLD) and a C-tag (EPEA) [@R43] for detection and purification, respectively. Purification was performed on an AKTA Pure 25 system (GE Healthcare, UK), consisting of an affinity step with CaptureSelect™ C-tag column (Thermo Fisher Scientific, UK) and a polishing size exclusion chromatography (SEC) using Superdex 200 16/60 PG (GE Healthcare, UK) in 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 (TBS). Purified protein was quantified by Nanodrop (Thermo Fisher Scientific, UK) and stored at -80°C until further use. A gene encoding the *Pv*DBPII HMP013 allele [@R19] (aa 194-521) was codon optimised for human expression and synthesised (Genewiz, USA). This sequence, with a 5' KpnI site and 3' XbaI site, was cloned into a mammalian expression plasmid in frame with an N-terminal mouse IgK light chain leader sequence and a C-terminal C-tag prior to the stop codon. Suspension EXPI293F cells (Thermo Fisher Scientific, UK) were transiently transfected and culture supernatants were harvested after 4 days. Purification was performed on an AKTA Pure 25 system (GE Healthcare, UK), consisting of an affinity step with CaptureSelect™ C-tag column (Thermo Fisher Scientific, UK) and a polishing SEC step using Superdex 200 Increase 10/300 GL (GE Healthcare, UK) in 20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.4 (TBS). Purified protein was quantified by Nanodrop (Thermo Fisher Scientific, UK) and stored at -80°C until further use.

The *Pv*AH, *Pv*O and *Pv*P alleles of *Pv*DBPII [@R44] used in the DARC binding-inhibition assays ([Figure 2](#F2){ref-type="fig"}) were a kind gift from Chetan Chitnis (Institute Pasteur, France).

Monobiotinylated *Pv*DBPII supernatant was produced for use in the BLI experiments ([Figures 1E-G](#F1){ref-type="fig"}) by transient transfection of suspension EXPI293F cells, using a plasmid encoding *Pv*DBPII (SalI) with C-terminal rat CD4 domains 3 and 4 followed by a biotin acceptor peptide obtained from Addgene (plasmid \#68529) and courtesy of Dr Julian Rayner (Wellcome Trust Sanger Institute, Hinxton, UK) [@R45]. This *Pv*DBPII plasmid was co-transfected with another plasmid encoding *E. coli* biotin ligase (BirA). Supernatant was harvested after 4 days, clarified, dialysed against PBS using snakeskin and concentrated \~10-fold using spin columns.

The production of the *Pv*DBPII and *Pv*DBPII subdomain 3 proteins used in the crystal complex ([Figure 6](#F6){ref-type="fig"}) and the subdomain 3 binding ELISA ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}) is described in ['Structural Methods'](#S29){ref-type="sec"} below.

The production of recombinant N-terminal DARC, used in the DARC-binding inhibition assays, has been previously described [@R19]. In brief; a gene encoding the first 60 amino acids of DARC Fyb allele (GenBank Accession \#ABA10433.1) followed by a thrombin cleavage site (LVPRGS) and an AviTag (GLNDIFEAQKIEWHE) was codon-optimised for *E. coli* expression and synthesised (GeneArt, Life Technologies). Cysteines 4, 51 and 54 of DARC were mutated to alanine. This sequence with 5' KpnI site and 3' BamHI site was cloned into a mammalian expression plasmid in-frame with an N-terminal human tissue plasminogen activator (tPA) leader sequence [@R20] and a C-terminal hexa-histidine (His6) tag prior to the stop codon. Suspension HEK293E cells grown in EXPI293 expression medium (Thermo Fisher Scientific, UK) were transiently transfected with plasmid and allowed to grow for three days before the supernatant was harvested, purified using a HisTrap Excel column (GE Healthcare, UK) and buffer exchanged into PBS. Purified protein was quantified by Nanodrop (Thermo Fisher Scientific, UK) and stored at -80°C until further use.

Recombinant monoclonal antibodies were transiently expressed in HEK293F cells using the Expi293™ *Expression* System (Thermo Fischer Scientific) according to the manufacturer's recommendations. Cognate heavy and light chain-coding plasmids were co-transfected at a 1:1 ratio. Supernatants were harvested by centrifuging the culture at 2500 x*g* for 15 min and filtering the supernatant with a 0.22 μm vacuum filter. All mAbs were purified using a 5 mL Protein G HP column (GE Healthcare) on an ÄKTA start FPLC system or an ÄKTA Pure FPLC system (both GE Healthcare). Equilibration and wash steps were performed with Dulbecco's PBS and mAbs were eluted in 0.1 M glycine pH 2.7. The eluates were pH equilibrated to 7.4 using 1.0 M Tris HCl pH 9.0 and immediately buffer-exchanged into Dulbecco's PBS and concentrated using an Amicon^®^ ultra centrifugal concentrator (Millipore) with a molecular weight cut-off of 30 kDa.

Bio-Layer Interferometry (BLI) {#S15}
------------------------------

BLI was carried out on an OctetRED384 (Pall FortéBio) using streptavidin-coated biosensors (Pall FortéBio) to immobilise *Pv*DBPII enzymatically monobiotinylated on a C-terminal AviTag™. Assays were carried out in 96-well format in black plates (Greiner). For epitope binning studies ([Figure 1E-G](#F1){ref-type="fig"}), a six-step sequential assay was performed: Baseline (PBS, 30 s); Protein immobilisation (neat supernatant, 120 s); Wash (PBS, 60 s); first mAb (mAb1) binding (300 nM mAb1, 120 s); Wash (PBS, 60 s); second mAb (mAb2) binding (150 nM mAb2, 120 s). "Relative binding" in [Figure 1E](#F1){ref-type="fig"} shows the ratio (Signal~mAb2~ with mAb1 bound)/(Signal~mAb2~ with no mAb1) where "Signal~mAb2~" was normalised for the amount of *Pv*DBPII bound to the biosensor, such that "Signal~mAb2~" = the raw signal in "mAb2 binding" divided by the raw signal in the "Protein immobilisation" phase. The resulting "binding profile" for any given mAb corresponds to the column of "relative binding values" under that mAb in the "relative binding" table. To establish the epitope bins, binding profiles between each mAb pair were correlated using a Pearson product-moment correlation coefficient, the values of which are shown in the "binding profile correlation" matrix in [Figure 1F](#F1){ref-type="fig"}. mAb pairs whose binding profile correlation was \> 0.7 were grouped into the same epitope bin ([Figure 1G](#F1){ref-type="fig"}).

Measurement of binding by ELISA {#S16}
-------------------------------

Qualitative mAb binding ELISAs such as those used in [Supplementary Figure 4](#SD1){ref-type="supplementary-material"} were carried out by coating *Pv*DBPII or *Pv*DBPII subdomain 3, produced as described in ['Structural Methods'](#S29){ref-type="sec"}, on Maxisorp flat-bottom 96-well ELISA plates (Nunc) at 2 μg/mL in 50 μL at 4 °C overnight. Plates were then washed twice with PBS and 0.05% Tween 20 (PBS/T) and blocked with 200 μL of Blocker™ Casein (Thermo Fischer Scientific) for 1 h. Next, wells were incubated with 10 μg/mL of mAb for approximately 45 min at 20 °C then washed 4 times with PBS/T before the addition of 50 μL of 1:1000 dilution of goat anti-human gamma-chain alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich) for 45 min at 20 °C. Wells were then washed 6 times with PBS/T and developed with 100 μL of p-nitrophenyl phosphate substrate at 1 mg/mL (Sigma-Aldrich) and optical density read at 405 nm (OD~405~) using a Model 550 Microplate Reader (Bio-Rad, UK).

Affinity determination by SPR {#S17}
-----------------------------

Data were collected on a Biacore X100 (GE Healthcare). Experiments were performed at 25 °C in Dulbecco's PBS + 0.005 % Polysorbate-20 (GE Healthcare). In [Figure 1](#F1){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"} a sensor chip protein A (GE Healthcare) was used to capture 50-100 RU of purified mAb diluted in SPR running buffer at a flow rate of 5 μL/min on flow cell 2. Next, an appropriate range (typically 20 nM-0.625 nM) of six 2-fold dilutions, with one replicate, of *Pv*DBPII (expressed in S2 cells as described above) was injected for 90 s at 60 μL/min and dissociation was measured for 1600 s (7200 s when necessary). Specific binding of the *Pv*DBPII protein to mAb was obtained by reference-subtracting the response of a blank surface from that of the mAb-coated surface. The sensor surface was regenerated with a 60 s pulse of 10 mM glycine-HCl pH 1.5 (GE Healthcare). Sensorgrams were fitted to a global Langmuir 1:1 interaction model, allowing determination of the kinetic association and dissociation rate constants using Biacore X100 evaluation software.

*Pv*DBPII-DARC binding inhibition assays {#S18}
----------------------------------------

This assay methodology has been previously reported [@R19],[@R29]. In brief; recombinant N-terminal DARC protein was coated onto Nunc-Immuno Maxisorp plates at 1 μg/mL. mAb samples were diluted down in a 2-fold series (starting at 100 μg/mL) and pre-incubated with *Pv*DBPII protein for 30 min at room temperature (RT). The pre-incubated *Pv*DBPII protein plus mAb mixture was then added to the DARC-coated plates (in duplicate wells). The plates were incubated for 1 h at 37 °C, washed and then incubated with anti-*Pv*DBPII polyclonal rabbit serum [@R20]. After a further wash step, the plates were incubated with a 1:1000 dilution of anti-rabbit IgG alkaline phosphatase (Sigma Aldrich, UK) and then developed with 1 mg/mL p-nitrophenyl phosphate in diethanolamine buffer (Pierce, UK). OD~405~ was read using a Model 550 Microplate Reader (Bio-Rad, UK) when control wells containing *Pv*DBPII protein and buffer only reached a value of 1.0. In one column of each 96 well plate, wells contained only mAb (100 μg/ml) and buffer (no *Pv*DBPII protein) and these 'background' OD~405~ values were subtracted from all test values. To calculate % binding-inhibition for each mAb sample the formula below was used: $$1 - (\textbf{OD}_{405}\ \textbf{value}\ \textbf{of}\ \textbf{mAb}\ \textbf{sample}/\textbf{OD}_{405}\ \textbf{value}\ \textbf{of}\ \textbf{negative}\ \textbf{control}\ \textbf{sample}) \times 100$$

Five allelic variants of recombinant *Pv*DBPII were used in the assay; Sal1, which was made in S2 cells as described above; *Pv*AH, *Pv*O and *Pv*P alleles [@R44], which were a kind gift from Chetan Chitnis (Insitute Pasteur, France); and *Pv*HMP013, which was sequenced from a vivax-infected patient in Australia [@R46]. The expression of recombinant *Pv*DBPII HMP013 protein has been previously described [@R19] and is summarised above. An anti-*Ebolavirus* glycoprotein (GP)-reactive human IgG1 mAb 'EBL040' [@R47] was used as a negative isotype control for mAb samples. Polyclonal human anti-*Pv*DBPII serum from the clinical trial [@R19] was used as the positive control.

Dot blot assay {#S19}
--------------

Briefly, 1.5 μL of each of the ten human anti-*Pv*DBPII mAbs, a human anti-Zaire Ebolavirus GP IgG1 mAb, recombinant *Pv*DBPII (all at 1 mg/mL) and PBS were spotted onto 0.2 μm nitrocellulose membrane and air-dried for 10 min. The membrane was then blocked in 3 % BSA + 3 % skimmed milk in PBS for 1 h and washed in PBS. It was then immersed in *P. vivax* culture supernatant for 1 h and washed again in PBS. This supernatant was taken from a short-term *in vitro* parasite viability assay using a frozen *P. vivax* blood-stage inoculum produced for controlled human malaria infection clinical trials (Minassian AM *et al.*, in preparation; Clinicaltrials.gov NCT03797989). Bound *Pv*DBPII was detected by incubating the membrane in anti-*Pv*DBPII rabbit serum[@R20] diluted 2000-fold in PBS followed by an alkaline phosphatase-conjugated anti-rabbit IgG mAb (clone RG-96, 403 Sigma-Aldrich) also diluted 1:2000, separated by two wash steps in PBS. After a final series of six PBS washes, the dot blot was developed with Sigmafast BCIP/NBT alkaline phosphatase substrate at 1 mg/mL (Sigma-Aldrich).

Genetic modification of *Plasmodium knowlesi* parasites {#S20}
-------------------------------------------------------

The genetic modification of *Plasmodium knowlesi* A1-H.1 strain [@R30] is described in detail elsewhere [@R31]. Briefly, parasites were modified using a two-plasmid CRISPR-Cas9 system, comprised of a plasmid (pCas/sg) providing Cas9, sgRNA, and a hDHFR-yFCU (for positive and negative selection) to create a locus specific double strand break and a separate "donor" DNA plasmid (pDonor) to act as the repair template. To create the *Pk*DBPα^OR^ or *Pv*DBP^OR^ lines the PkDBPα locus (sgRNA: GCTGATCCAGGTTCTCAATC) was targeted using a pDonor plasmid containing full length recodonised PkDBPα or PvDBP (SalI) genes respectively, both flanked by 500 bp homology regions targeting the 5'UTR and 3'UTR of PkDBPα. To create the *Pk*DBPα^OR^/Δβγ and *Pv*DBP^OR^/Δβγ lines this process was repeated in an A1-H.1 line which had a natural deletion of *Pk*DBPβ (due to a truncation of chromosome 14) and then a subsequent round of gene editing was used to delete the *Pk*DBPγ locus (sgRNA: CATGCAACAATTTACACCCC) using a pDonor plasmid containing a spacer sequence flanked by 500 bp homology regions targeting the 5'UTR and 3'UTR of *Pk*DBPγ.

Assays of growth inhibitory activity (GIA) with *Plasmodium knowlesi* lines {#S21}
---------------------------------------------------------------------------

### *In vitro* parasite culture and synchronisation {#S22}

Human RBC-adapted parasites were maintained in culture as previously described [@R30]. Briefly, parasites were grown at 2 % haematocrit in O+ human RBC, which were prepared twice monthly. Culture medium contained 10 % heat-inactivated pooled human serum mixed with RPMI 1640 supplemented with 25 mM HEPES, 35 μM hypoxanthine, 2 mM L-glutamine and 20 μg/mL gentamycin. Parasite cultures were synchronised at trophozoite/schizont stage by magnetic separation (MACS LS columns, Miltenyi Biotech).

### *In vitro* assay of GIA {#S23}

Methodology was adapted from the protocol of the International GIA Reference Centre at NIH, USA [@R48]. Synchronised trophozoites were adjusted to 1.5 % parasitaemia, and 20 μL aliquots were pipetted into 96-well flat/half area tissue culture cluster plates (Appleton Woods). 20 μL test antibody or controls were added in duplicate or triplicate test wells over a concentration range (usually; 1, 0.5, 0.25, 0.125, 0.0625, 0.0312, 0.015 and 0.0075 mg/mL) and incubated for one erythrocytic parasite cycle (26-30 h). Parasitaemia was measured using the lactate dehydrogenase (pLDH) activity assay following standard protocols [@R49]. Percentage GIA was calculated as below; $$\mathbf{\%}\ \textbf{GIA} = 100 - 100\ ({\textbf{Sample}\ \textbf{A}}_{650} - {\textbf{Uninfected}\ \textbf{RBC}\ \textbf{A}}_{650})/({\textbf{Infected}\ \textbf{ControlA}}_{650} - {\textbf{Uninfected}\ \textbf{RBC}\ \textbf{A}}_{650})$$

An anti-DARC VHH camelid nanobody [@R50], a kind gift from Dr Olivier Bertrand (INSERM, France) was included in the test plate as a positive control in every assay (at a final concentration of 6, 3 or 1.5 μg/mL) and an anti-*Ebolavirus* glycoprotein-reactive human IgG1 mAb as a negative isotype control for mAb samples. The assays were performed using five different lines of *Plasmodium knowlesi* parasites; the non-transgenic strain (PkA1-H.1); two transgenic lines containing the *Pv*DBP gene (*Pv*DBP^OR^ and *Pv*DBP^OR^/Δβγ) and two transgenic control lines (*Pk*DBPα^OR^ and *Pk*DBPα^OR^/Δβγ) [@R31]. In the mAb synergy assays ([Figure 5](#F5){ref-type="fig"}) 'Bliss additivity' between two mAbs (mAb A and mAb B) was calculated using the formula below. $$\textbf{GIA}\ \left\lbrack {\textbf{A} + \textbf{B}} \right\rbrack\ \textbf{Bliss} = \left\lbrack {1 - \left( {1 - \frac{\textbf{GIA}\ \textbf{A}}{100}} \right) \ast \left( {1 - \frac{\textbf{GIA}\ \textbf{B}}{100}} \right)} \right\rbrack \ast 100$$

*Ex-vivo Plasmodium vivax* invasion assays {#S24}
------------------------------------------

The assay methodology has been previously described [@R51],[@R52]. The major steps are summarised below.

### Purification of reticulocytes from umbilical cord blood {#S25}

20 mL aliquots of umbilical cord blood were collected from consenting volunteers (OXTREC 027-025 (Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom) and MUTM 2008-215 from the Ethics Committee of the Faculty of Tropical Medicine (Mahidol University, Bangkok, Thailand)) in lithium heparin tubes and the white blood cells and platelets depleted using Non-woven filters™ (Antoshin). The RBC were then layered onto 70 % isotonic Percoll, centrifuged and the resulting band of enriched reticulocytes was incubated with anti-CD71 MicroBeads (Miltenyi) before being passed through a large selection (LS) column (Miltenyi) to obtain a CD71-depleted (negative) fraction and a CD71-rich fraction (positive). The purity levels of these CD71+ fractions were assessed with microscopy using new methylene blue staining (Sigma-Aldrich).

### Purification of schizonts from *ex-vivo Plasmodium vivax*-infected blood samples {#S26}

5 mL samples of whole blood were collected from consenting patients (OXTREC 027-025 (Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom) and MUTM 2008-215 from the Ethics Committee of the Faculty of Tropical Medicine (Mahidol University, Bangkok, Thailand)) diagnosed with *Plasmodium vivax* malaria and rapidly transported at room temperature back to the laboratory. Samples were not collected from patients who had taken antimalarial or antimicrobial drugs within the previous month, or whose parasitaemia was \< 0.1 % on smear microscopy. The samples were leukodepleted using Non-woven filters™ (Antoshin), and the parasites were cultured to schizont stage. The culture was then treated with trypsin, overlaid on a 45 % Percoll (isotonic) cushion and centrifuged to isolate a fine band of concentrated schizonts for use in the assay.

### Invasion assay {#S27}

The concentrated schizont preparation was mixed with the enriched reticulocyte fraction at a ratio of 1:6, giving a starting schizont parasitaemia of \~14 %. The mixture was diluted to 1.3 % haematocrit in 300 μL of complete McCoy 5A medium and cultured in 96-well cell culture plates in an atmosphere of 5 % O~2~ at 37.5 °C. Test antibodies and controls were buffer exchanged into *Pv* culture medium (McCoy 5A medium (Gibco) supplemented with 2.4 g/L D-glucose, 40 mg/mL gentamycin sulfate, and 20% heat-inactivated human AB serum) and added to the final invasion assay mixture at the desired concentration. In the case of the anti-*Pv*DBPII mAbs this was 1 mg/mL. The anti-DARC nanobody, at 25 μg/mL, and the recombinant IgG1 anti-*Ebolavirus* mAb, at 1mg/mL, were added to all assays as positive and negative controls respectively. Maturation was obtained after incubation for an average of 24 h. At the end of the incubation period, thin smears (each made with 1 μL packed cells) were made, and stained with Giemsa (Sigma-Aldrich). The number of ring stages and trophozoites per 4000 erythrocytes was determined by examining the Giemsa thin film smears by light microscopy. For isolates \#1-3, the invasion assays were performed in Singapore using cryopreserved Thai *Plasmodium vivax* isolates and reticulocyte invasion inhibition was quantified by flow cytometry as previously described [@R51].

### Sequencing of the *Pv* DBPII gene from Thai isolates {#S28}

Genomic DNA was extracted either from an aliquot (200 μL) of the initial blood sample or from a dried blood spot, using the DNeasy Blood and Tissue kit (QIAGEN). PCR amplification was performed on 1 μL purified genomic DNA in a total volume of 50 μL, containing 1x PCR buffer, 2.5 mM MgCl~2~, 0.2 mM of each dNTP, 2 μM each primer (forward 5' -- gtg act ggg cat gag gga aat tct cg and reverse 5' -- gcg tag aat ctc ctg gaa cct tct cc) and 1.25U of AmpliTaq Gold DNA polymerase (Applied Biosystems). The cycling conditions were: 95 °C for 5 min followed by 30 cycles at 94 °C for 1 min, 63 °C for 2 min, and 72 °C for 2 min. The product was purified using the QIAquick PCR purification kit (QIAGEN) and then sequenced (GATC biotech).

Structural Methods {#S29}
------------------

### Protein Cloning, Expression and Purification {#S30}

*Pv*DBPII coding region (residues 211-507; SalI sequence) was cloned into pET15b vector. This vector allowed expression of the protein with an N-terminal His6 tag and a TEV cleavage site, in *E. coli* (BL21-DE3 strain). The transformed bacteria were induced with 1 mM IPTG at an optical density of 0.8 at 600 nm. *Pv*DBPII was expressed exclusively in inclusion bodies and was prepared as previously described [@R15]. In short, the inclusion bodies were solubilised in 6 M guanidine hydrochloride, 20 mM Tris pH8, 300 mM NaCl, and refolded by flash-dilution into 400 mM L-arginine, 50 mM Tris pH8, 10 mM EDTA, 0.1 mM PMSF, 3 mM reduced glutathione, and 0.3 mM oxidised glutathione. Refolded proteins were buffer exchanged into 20 mM Tris pH8, 150 mM NaCl, 20 mM imidazole and then affinity purified on NiNTA resin. The His-tag was removed by TEV protease cleavage and the tagless *Pv*DBPII was separated from the His-tag on NiNTA resin and purified by SEC (S75 16/60, GE Healthcare) into 20 mM Hepes pH7.5, 150 mM NaCl.

Subdomain3 (Sd3) (residues 211-508) was subcloned from the *Pv*DBPII construct in the pET15b vector. Sd3 also expressed in *E. coli* BL21 (DE3) cells in the insoluble fraction and was solubilised in 6 M guanidine hydrochloride, 20 mM Tris (pH8), 150 mM NaCl, 20 mM imidazole. Sd3 was then refolded by binding to a NiNTA column and gradually decreasing the concentration of guanidine hydrochloride, until the protein was in 20 mM Tris (pH8), 150 mM NaCl, 20 mM imidazole. The refolded Sd3 protein was then eluted and further purified using SEC (S75 16/60 GE Healthcare) into 20 mM Hepes pH7.5, 150 mM NaCl.

### Fab Generation and Purification {#S31}

Fab fragments for DB9 were generated from IgG by incubating with immobilised papain (ThermoFisher Scientific) for 16 h at 37 °C. The Fab was separated from the un-cleaved DB9 and Fc regions using protein A resin (ThermoFisher Scientific). The Fab fragments were then purified by SEC into 20 mM Hepes pH7.5, 150 mM NaCl.

### Protein Cystallisation and Data Collection {#S32}

*Pv*DBPII and DB9Fab were mixed in a 1.2:1 molar ratio and incubated at RT for 1 h. The complex was purified by SEC (S75, GE Healthcare) in 20 mM Hepes pH7.5, 150 mM NaCl. Broad crystallisation trials were set up by sitting-drop vapour diffusion in SwisSci 96-well plates by mixing 100 nl protein with 100 nl reservoir solution. Crystals grew in the reservoir solution of 45 % v/v polypropylene glycol 400, 10% v/v ethanol and were then cryo-cooled in liquid nitrogen. Data were collected on beamline I03 at Diamond Light Source at a wavelength of 0.97625Å and were indexed using XDS [@R53] and scaled using Scala [@R54] to a resolution of 3.04 Å.

### Structure Solution {#S33}

The *Pv*DBPII:DB9Fab structure was solved by molecular replacement in Phaser [@R55] using the known structures of *Pv*DBPII (PDB 4NUV) and a human mAb Fab fragment (PDB: 3DIF), separated into the variable and constant regions, as search models. This identified one copy of the *Pv*DBPII:DB9 complex in the asymmetric unit. Refinement and rebuilding was completed using Buster [@R56] and Coot [@R57], respectively. The final Ramachandran plot showed 94.9% of residues in the favoured region, 5.1% in the allowed region and none in the disallowed region.

### Statistical Analyses {#S34}

Data were analysed using GraphPad Prism version 6.07 for Windows (GraphPad Software Inc.). In [Figure 3A](#F3){ref-type="fig"}, a four-parameter sigmoidal dose-response curve was fitted to the relationship between log10 (antibody concentration) and percentage GIA for each dataset and used to interpolate EC~30~ values. In [Figure 3B](#F3){ref-type="fig"}, the nonparametric Spearman's rank correlation coefficient (ρ) was used to assess a correlation between the variables *k*~on~/*k*~off~/*K*~D~ and GIA EC~30~. In all statistical tests the *P* values reported are two-tailed with *P* \< 0.05 considered significant.
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![Binding kinetics and epitope bins for the human anti-*Pv*DBPII mAb panel.\
Kinetic rate constants of binding for ten human mAbs (DB1-DB10) to *Pv*DBPII as determined by SPR. **(A)** Association rate constant (*k*~on~); **(B)** Dissociation rate constant (*k*~off~); **(C)** Association constant (1/*K*~D~); and **(D)** Iso-affinity plot of *k*~on~ against *k*~off~. **(E)** A "relative binding" matrix showing the fraction of a mAb bound to *Pv*DBPII in the presence of a second bound mAb. Assays were conducted in both orientations. Boxes are colour-coded with ≥ 0.75 in blue, 0.75 \> X \> 0.05 in pink and ≤ 0.05 in red. Negative values were normalised to 0 and values \>1 were normalised to 1. **(F)** A "binding profile correlation" matrix showing the Pearson product-moment correlation values of each mAb pair. The correlation threshold was set at 0.7; values equal to or above this are coloured in red as the threshold chosen to represent competition. **(G)** Epitope bins determined from E and F.](emss-82682-f001){#F1}

![Inhibition of the binding of recombinant *Pv*DBPII to DARC ectodomain.\
**(A)** Assessment of the % binding of five naturally occurring variants of *Pv*DBPII to the DARC ectodomain *in vitro* in the presence of 100 μg/mL concentration of each mAb (DB1-DB10). Individual titration curves are shown in [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}. "αDBP" is polyclonal human anti-*Pv*DBPII serum at 1:5 dilution while 'ebola' is an anti-*Ebolavirus* recombinant human IgG1 mAb included as a negative control. Data points represent the mean of three technical replicates, while the error bars represent the standard deviation. **(B)** Sequence polymorphisms of *Pv*DBPII variants used in the assay. Numbering is according to the SalI reference sequence. Amino acid polymorphisms are indicated for the *Pv*DBPII variants (P, O, AH and HMP013). Amino acids that are the same as the SalI reference sequence are black, those divergent from SalI are red and \* indicates the absence of a leucine insertion between V429 and P430 in HMP013.](emss-82682-f002){#F2}

![Growth inhibition of transgenic *Plasmodium knowlesi* (*Pk*) lines expressing *Pv*DBP.\
**(A)** Assays of growth Inhibitory activity (GIA) by the ten anti-*Pv*DBPII human mAbs against five different *Pk* lines**:** 'Wild type' *Pk* (A1-H.1); *Pk*DBPα^OR^; *Pk*DBPα^OR^/Δβγ; *Pv*DBP^OR^ and *Pv*DBP^OR^/Δβγ. Inhibition was tested in a two-fold dilution series starting at 1 mg/mL. Data points represent the mean of three technical replicates, while the error bars represent the standard deviation. The EC~50~ values (interpolated by non-linear regression) are shown in ascending rank order for the seven mAbs which reached \>50 % GIA against *Pv*DBP^OR^/Δβγ at the maximum concentration (1 mg/mL). **(B)** *k*~on~ (on-rate), *k*~off~ (off-rate) and *K*~D~ (dissociation constant), plotted against GIA EC~30~ for *Pv*DBP^OR^/Δβγ. EC~30~ values were used to include weaker-neutralising mAbs and were interpolated from non-linear regression curves. Kinetic data are as [Figure 1](#F1){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. Spearman's rank correlation coefficient (ρ) and *P* value are shown.](emss-82682-f003){#F3}

![Inhibition of invasion of reticulocytes by Thai *Plasmodium vivax* clinical isolates.\
**(A)** *Plasmodium vivax ex-vivo* invasion assays were performed with thirteen separate isolates of infected blood from local patients. Each data point represents the % inhibition of each antibody against one of the thirteen isolates. All antibodies were tested at a final concentration of 1 mg/mL, except the positive control anti-DARC VHH (VHH) which was assayed at 25 μg/mL. The red bars represent the median % inhibition for each antibody. A recombinant human IgG1 anti-*Ebolavirus* mAb (ebola) was used as a negative control at 1mg/mL. **(B)** Percentage invasion inhibition by mAbs tested against the two Thai *Plasmodium vivax* isolates which share the *Pv*DBPII gene sequence of SalI; isolate \#4 (left hand bar of each pair) and isolate \#7 (right hand bar of each pair). This demonstrates the degree of correlation with the hierarchy of mAb inhibition in the transgenic *Plasmodium knowlesi* GIA assays ([Figure 3A](#F3){ref-type="fig"}). **(C)** Amino acid polymorphisms found within the *Pv*DBPII gene segment of the eight Thai Pv isolates for which we obtained sequence information. The vaccine homologous SalI reference sequence is shown in the bottom row. Amino acids that are the same as the reference sequence black, divergent residues are red and \* represents absence of a leucine insertion between V429 and P430 in the SalI reference sequence. **(D)** Summary matrix showing the percentage inhibition of invasion by each mAb for each of the sequenced strains. The positive control was the camelid anti-DARC nanobody (VHH) at 25 μg/mL and the negative control was a recombinant human IgG1 anti-*Ebolavirus* mAb (ebola) at a concentration of 1 mg/mL.](emss-82682-f004){#F4}

![Assessment of synergy, additivity and antagonism by anti-*Pv*DBPII human mAb combinations.\
Assays of growth inhibitory activity (GIA) were performed to assess the inhibitory activity of DB9 in combination with the other mAbs against the *Pv*DBP^OR^ transgenic *Plasmodium knowlesi* line. DB9 was held at a fixed concentration of 25 μg/mL, while the other mAbs are in a two-fold dilution series starting at 100 μg/mL. The black line shows the % inhibition of each mAb in the absence of DB9. The red line shows the predicted additive inhibition ('Bliss additivity' as calculated in the equation in [Methods](#S8){ref-type="sec"}) of the indicated mAb plus DB9 at 25 μg/mL. The blue line shows the actual observed % inhibition of the two combined mAbs. The dotted black line gives the % inhibition of DB9 alone at 25 μg/mL. Data points represent the mean of three technical replicates, while the error bars represent the standard deviation.](emss-82682-f005){#F5}

![The structural basis for inhibition of *Pv*DBPII by antibody DB9.\
**(A)** The structure of *Pv*DBPII (pink) bound to the Fab fragment of DB9 (blue). *Pv*DBPII is shown in two shades of pink, with subdomains 1 and 2 in light pink and subdomain 3 in dark pink. DB9 is in two shades with the light chain in light blue and the heavy chain in dark blue. **(B)** *Pv*DBPII is shown in surface representation in grey, with residues known to be polymorphic highlighted according to their sequence entropy (yellow = 0.15-0.3, orange = 0.3-0.45 and red \> 0.45). DB9 is in blue, and binds to a conserved region of *Pv*DBPII. **(C)** The structure of *Pv*DBPII:DB9 complex superimposed on the structure of the *Pv*DBPII dimer structure bound to a peptide from the DARC ectodomain, indicating that DB9 may prevent the binding of *Pv*DBP to DARC in the context of the reticulocyte membrane.](emss-82682-f006){#F6}
